Deborah Mukherji· @dmukherji · X·· 2 天前评分70
正文 · 原文
#ESMO26, TALAPRO-3 showed improved rPFS with talazoparib + enzalutamide in HRR-altered mCSPC without clinically meaningful deterioration in overall QoL versus enzalutamide alone
Important benefit–risk data for treatment intensification @AzadOncology @OncoAlert
335 浏览 · 8 赞 · 8 转发 · 0 回复
会议摘要
Utility of ctDNA tumor fraction (TF) as a prognostic biomarker in TALAPRO-3: phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in patients (pts) with homologous recombination repair (HRR) gene–mutated metasta
https://esmocongress.esmo.org来源：Deborah Mukherji · x.com